Akero Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
AKRO Nasdaq 8731 https://www.akerotx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Akero Therapeutics Inc

Akero Therapeutics Reports First Quarter 2022 Financial Results - May 6th, 2022 11:00 am
Akero Therapeutics to Present at Upcoming Healthcare Conferences in May - May 2nd, 2022 11:30 am
We're Hopeful That Akero Therapeutics (NASDAQ:AKRO) Will Use Its Cash Wisely - Mar 7th, 2022 9:13 am
Akero Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results - Feb 25th, 2022 12:00 pm
Akero Therapeutics Completes Enrollment of Phase 2b HARMONY Study in Pre-Cirrhotic NASH Patients - Feb 8th, 2022 1:00 pm
Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year? - Jan 14th, 2022 2:40 pm
Akero Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference - Jan 4th, 2022 9:05 pm
Akero Therapeutics to Present at the Evercore ISI 4th Annual HealthCONx Virtual Conference - Nov 26th, 2021 10:28 pm
Wall Street Analysts Think Akero Therapeutics, Inc. (AKRO) Could Surge 92%: Read This Before Placing a Bet - Nov 17th, 2021 3:07 pm
Akero Presents New Analysis of Phase 2a BALANCED Study Data Showing Additional Qualitative Evidence of Histological Improvement in EFX-treated NASH Patients after 16 Weeks of Treatment - Nov 12th, 2021 1:01 pm
Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update - Nov 12th, 2021 12:00 pm
Akero Therapeutics to Present at the Jefferies London Healthcare Conference - Nov 9th, 2021 9:15 pm
Akero Therapeutics’ NASH Treatment Gets Fast Track Designation; Shares Rise - Oct 20th, 2021 2:03 pm
Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH - Oct 19th, 2021 8:15 pm
Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference - Oct 5th, 2021 12:00 pm
Here's Why We're Not Too Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Situation - Sep 8th, 2021 10:21 am
Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference - Sep 7th, 2021 12:00 pm
Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update - Aug 13th, 2021 11:00 am
Akero Therapeutics Appoints Judy Chou, Ph.D., to its Board of Directors - Jul 14th, 2021 12:00 pm
Akero's NASH Candidate Shows Substantial Liver Fat Reductions After Four Months Of Treatment - Jul 8th, 2021 5:24 pm